Title
Category
Credits
Event date
Cost
  • Cardiology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Please Note: Credit Is No Longer Available Initiating and optimizing in-hospital guideline-directed medical therapies (GDMT) remains a challenge for clinicians treating patients with worsening HFrEF. Join Drs. Muthiah Vaduganathan and Michelle Kittleson, as they discuss opportunities and strategies to employ evidence-based therapies to address these challenges.Supported through an independent educational grant from Merck.
  • Cardiology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Please Note: Credit Is No Longer Available Heart failure is a major public-health problem resulting in substantial morbidity and mortality for the US. Unfortunately, challenges and barriers to effective use of guideline-directed medical therapies (GDMT) among hospitalized patients with HFrEF remain. Join Drs. Muthiah Vaduganathan and Amulya Nagarur as they discuss practical strategies and insights into using GDMT, and opportunities for multidisciplinary partnerships when treating these patients.
  • Cardiology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Please Note: Credit Is No Longer Available Join Drs. Muthiah Vaduganathan and Javed Butler for this on-demand online activity, as they examine novel methodologies to address the clinical worsening of HFrEF, with a focus on recently-reported results from the VICTORIA trial.Supported through an independent educational grant from Merck.
  • Cardiology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
All clinicians managing patients with non-dialysis-dependent chronic kidney disease or heart failure must be aware of the deleterious impacts of concomitant anemia and the established, emerging, and practice-changing role of intravenous (IV) iron therapies. The vicious cycle of cardiorenal anemia syndrome (CRAS)—the pathologic triad wherein the three conditions are each capable of causing and/or being caused by the other—can be effectively mitigated and managed with IV iron.
  • Cardiology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
All clinicians managing patients with non-dialysis-dependent chronic kidney disease or heart failure must be aware of the deleterious impacts of concomitant anemia and the established, emerging, and practice-changing role of intravenous (IV) iron therapies. The vicious cycle of cardiorenal anemia syndrome (CRAS)—the pathologic triad wherein the three conditions are each capable of causing and/or being caused by the other—can be effectively mitigated and managed with IV iron.
  • Cardiology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • ICPE
  • Participation
$0.00
Please Note: Credit Is No Longer Available Listen on CEConversations
  • Cardiology
10/01/2022
$0.00
This timely and dynamic educational activity will begin with a foundational circumscription of iron deficiency (ID) pathophysiology and clinical gravity in heart failure (HF), particularly in heart failure with reduced ejection fraction (HFrEF), as well as the impact of elevated hepcidin on iron supplementation strategies.
  • Cardiology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • ICPE
  • Participation
11/05/2022
$0.00
To register in advance click here: https://us06web.zoom.us/webinar/register/WN_lNOW5KvGQcy37LkauNu7fg